We sought to validate our ALK immunoassays using both neuroblastoma cell lines and tumor tissue from the Th‐ALKF1174L/MYCN transgenic model, which has previously demonstrated the inadequacy of the first‐generation ALK inhibitor, crizotinib, to elicit therapeutic responses in ALK F1174L‐driven neuroblastomas (Berry et al., 2012). This evidence concerns the gene MYCN and neuroblastoma.